ODT - Odonate Therapeutics: Small Biotech Firm Seeks To Improve Quality Of Life For Breast Cancer Patients
Shares of Odonate Therapeutics (ODT) have lost 45% of their value since the company's December 2017 IPO was done at a price point of $24 per share. Over the past three months, the stock has lost a quarter of its value.
Regardless of weak technicals, the fundamental story seems quite intriguing to me (lead asset is orally administered taxane with several advantages over currently approved options) and I'm looking forward to digging deeper.
Chart
Figure 1: ODT daily advanced chart (Source: Finviz)
Figure 2: ODT 15-minute chart (Source: Finviz)
When looking at charts,